Literature DB >> 25587136

The value of monitoring to control evolving populations.

Andrej Fischer1, Ignacio Vázquez-García2, Ville Mustonen3.   

Abstract

Populations can evolve to adapt to external changes. The capacity to evolve and adapt makes successful treatment of infectious diseases and cancer difficult. Indeed, therapy resistance has become a key challenge for global health. Therefore, ideas of how to control evolving populations to overcome this threat are valuable. Here we use the mathematical concepts of stochastic optimal control to study what is needed to control evolving populations. Following established routes to calculate control strategies, we first study how a polymorphism can be maintained in a finite population by adaptively tuning selection. We then introduce a minimal model of drug resistance in a stochastically evolving cancer cell population and compute adaptive therapies. When decisions are in this manner based on monitoring the response of the tumor, this can outperform established therapy paradigms. For both case studies, we demonstrate the importance of high-resolution monitoring of the target population to achieve a given control objective, thus quantifying the intuition that to control, one must monitor.

Entities:  

Keywords:  adaptive cancer therapy; drug resistance; stochastic optimal control

Mesh:

Year:  2015        PMID: 25587136      PMCID: PMC4313848          DOI: 10.1073/pnas.1409403112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

Review 1.  Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology.

Authors:  I M Rouzine; A Rodrigo; J M Coffin
Journal:  Microbiol Mol Biol Rev       Date:  2001-03       Impact factor: 11.056

2.  Dynamics of targeted cancer therapy.

Authors:  Ivana Bozic; Benjamin Allen; Martin A Nowak
Journal:  Trends Mol Med       Date:  2012-05-15       Impact factor: 11.951

3.  The life history of 21 breast cancers.

Authors:  Serena Nik-Zainal; Peter Van Loo; David C Wedge; Ludmil B Alexandrov; Christopher D Greenman; King Wai Lau; Keiran Raine; David Jones; John Marshall; Manasa Ramakrishna; Adam Shlien; Susanna L Cooke; Jonathan Hinton; Andrew Menzies; Lucy A Stebbings; Catherine Leroy; Mingming Jia; Richard Rance; Laura J Mudie; Stephen J Gamble; Philip J Stephens; Stuart McLaren; Patrick S Tarpey; Elli Papaemmanuil; Helen R Davies; Ignacio Varela; David J McBride; Graham R Bignell; Kenric Leung; Adam P Butler; Jon W Teague; Sancha Martin; Goran Jönsson; Odette Mariani; Sandrine Boyault; Penelope Miron; Aquila Fatima; Anita Langerød; Samuel A J R Aparicio; Andrew Tutt; Anieta M Sieuwerts; Åke Borg; Gilles Thomas; Anne Vincent Salomon; Andrea L Richardson; Anne-Lise Børresen-Dale; P Andrew Futreal; Michael R Stratton; Peter J Campbell
Journal:  Cell       Date:  2012-05-17       Impact factor: 41.582

4.  Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer.

Authors:  Robert A Beckman; Gunter S Schemmann; Chen-Hsiang Yeang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-13       Impact factor: 11.205

Review 5.  Role of optimal control theory in cancer chemotherapy.

Authors:  G W Swan
Journal:  Math Biosci       Date:  1990-10       Impact factor: 2.144

Review 6.  Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.

Authors:  Robert J Gillies; Daniel Verduzco; Robert A Gatenby
Journal:  Nat Rev Cancer       Date:  2012-06-14       Impact factor: 60.716

Review 7.  Managing drug resistance in cancer: lessons from HIV therapy.

Authors:  Christoph Bock; Thomas Lengauer
Journal:  Nat Rev Cancer       Date:  2012-06-07       Impact factor: 60.716

8.  Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model.

Authors:  Andrew R Wargo; Silvie Huijben; Jacobus C de Roode; James Shepherd; Andrew F Read
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-03       Impact factor: 11.205

9.  EMu: probabilistic inference of mutational processes and their localization in the cancer genome.

Authors:  Andrej Fischer; Christopher J R Illingworth; Peter J Campbell; Ville Mustonen
Journal:  Genome Biol       Date:  2013-04-29       Impact factor: 13.583

10.  THetA: inferring intra-tumor heterogeneity from high-throughput DNA sequencing data.

Authors:  Layla Oesper; Ahmad Mahmoody; Benjamin J Raphael
Journal:  Genome Biol       Date:  2013-07-29       Impact factor: 13.583

View more
  16 in total

Review 1.  The potential impact of coinfection on antimicrobial chemotherapy and drug resistance.

Authors:  Ruthie B Birger; Roger D Kouyos; C Jessica E Metcalf; Ted Cohen; Emily C Griffiths; Silvie Huijben; Michael J Mina; Victoriya Volkova; Bryan Grenfell
Journal:  Trends Microbiol       Date:  2015-05-29       Impact factor: 17.079

2.  Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy.

Authors:  Jeffrey B West; Mina N Dinh; Joel S Brown; Jingsong Zhang; Alexander R Anderson; Robert A Gatenby
Journal:  Clin Cancer Res       Date:  2019-04-16       Impact factor: 12.531

Review 3.  Modeling Tumor Clonal Evolution for Drug Combinations Design.

Authors:  Boyang Zhao; Michael T Hemann; Douglas A Lauffenburger
Journal:  Trends Cancer       Date:  2016-03

4.  Tuning Spatial Profiles of Selection Pressure to Modulate the Evolution of Drug Resistance.

Authors:  Maxwell G De Jong; Kevin B Wood
Journal:  Phys Rev Lett       Date:  2018-06-08       Impact factor: 9.161

Review 5.  Evolutionary determinants of cancer.

Authors:  Mel Greaves
Journal:  Cancer Discov       Date:  2015-07-20       Impact factor: 39.397

6.  Modelling bistable tumour population dynamics to design effective treatment strategies.

Authors:  Andrei R Akhmetzhanov; Jong Wook Kim; Ryan Sullivan; Robert A Beckman; Pablo Tamayo; Chen-Hsiang Yeang
Journal:  J Theor Biol       Date:  2019-05-09       Impact factor: 2.405

7.  Dynamics of preventive vs post-diagnostic cancer control using low-impact measures.

Authors:  Andrei R Akhmetzhanov; Michael E Hochberg
Journal:  Elife       Date:  2015-06-25       Impact factor: 8.140

8.  How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient.

Authors:  Elsa Hansen; Robert J Woods; Andrew F Read
Journal:  PLoS Biol       Date:  2017-02-09       Impact factor: 8.029

9.  Estimating the predictability of cancer evolution.

Authors:  Sayed-Rzgar Hosseini; Ramon Diaz-Uriarte; Florian Markowetz; Niko Beerenwinkel
Journal:  Bioinformatics       Date:  2019-07-15       Impact factor: 6.937

Review 10.  Tumour Cell Heterogeneity.

Authors:  Laura Gay; Ann-Marie Baker; Trevor A Graham
Journal:  F1000Res       Date:  2016-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.